Inventiva (NASDAQ:IVA) Stock Price Breaks Above Fifty Day Moving Average – What’s Next?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $3.80 and traded as high as $3.99. Inventiva shares last traded at $3.83, with a volume of 3,248,993 shares traded.

Analysts Set New Price Targets

Several research firms have issued reports on IVA. Truist Financial upped their price target on Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a report on Friday, October 2nd. Piper Sandler reissued an “overweight” rating on shares of Inventiva in a research report on Wednesday, September 16th. Weiss Ratings upgraded shares of Inventiva from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 23rd. Wall Street Zen upgraded Inventiva from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, Cantor Fitzgerald initiated coverage on Inventiva in a research note on Friday, July 17th. They issued an “overweight” rating for the company. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Inventiva has a consensus rating of “Buy” and a consensus price target of $15.86.

Inventiva Stock Up 4.9%

The company has a 50 day moving average of $3.80 and a 200 day moving average of $4.88.

Inventiva (NASDAQ:IVA) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The company had revenue of $0.75 million for the quarter. On average, research analysts expect that Inventiva S.A. Sponsored ADR will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On Inventiva

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP acquired a new position in Inventiva during the first quarter valued at approximately $1,111,000. Engineers Gate Manager LP increased its stake in shares of Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after purchasing an additional 43,280 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Inventiva by 78.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company’s stock worth $142,000 after purchasing an additional 17,000 shares during the last quarter. Platt Investment Counsel LLC acquired a new stake in Inventiva in the 3rd quarter valued at approximately $45,000. Finally, Commonwealth Equity Services LLC increased its position in Inventiva by 7.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 89,853 shares of the company’s stock worth $332,000 after buying an additional 5,857 shares during the period. 19.06% of the stock is currently owned by institutional investors and hedge funds.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.